Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.45 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705214 | 0.89 | PDE5A (0.47) | PDE5AHRH2DRD4PDE2ASMO | |
| SCHEMBL6133154 | 0.87 | HRH2 (0.46) | PDE5AHRH2DRD4PDE2AHTR2A | |
| Hydrochloric Acid SCHEMBL5705131 | 0.85 | PDE5A (0.47) | PDE5APDE2A | |
| SCHEMBL7188251 | 0.78 | EP300 (0.48) | PDE5ADRD4PDE2ASMN1; SMN2 | |
| SCHEMBL7178143 | 0.75 | EP300 (0.43) | PDE5ADRD4PDE2ASMN1; SMN2 | |
| SCHEMBL7178145 | 0.75 | EP300 (0.43) | PDE5ADRD4PDE2ASMN1; SMN2 | |
| SCHEMBL7179341 | 0.75 | EP300 (0.43) | PDE5ADRD4PDE2ASMN1; SMN2 | |
| SCHEMBL7191329 | 0.72 | PDE7A (0.45) | PDE5ADRD4PDE2A | |
| SCHEMBL7183896 | 0.69 | PDE7A (0.45) | PDE5ADRD4PDE2A | |
| SCHEMBL7182981 | 0.69 | PDE7A (0.45) | PDE5ADRD4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | PDE5A 612/4885HRH2 60/4885DRD4 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.